CLINICAL TRIALS PROFILE FOR PIPERACILLIN SODIUM

All Clinical Trials for PIPERACILLIN SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003805 ↗	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-11-01	RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00389987 ↗	Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2001-09-01	This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.
NCT00873327 ↗	Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates	Completed	Phillip Brian Smith	Phase 1	2009-10-01	This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety of piperacillin-tazobactam in infants < 61 days of age with suspected sepsis. There will be four cohorts of 8 infants each: 1. < 32 weeks gestational age (GA) and < 14 days postnatal age (PNA) 2. < 32 weeks gestational age and >=14 days postnatal age 3. >=32 weeks gestational age and < 14 days postnatal age 4. >=32 weeks gestational age and >=14 days postnatal age. The study requires administration of 6 doses of study drug along with other antimicrobials per standard of care followed by 1 week of safety monitoring. Four 200 µL pK samples will be obtained at steady state. The risks are reasonable vs. the benefits and have been minimized appropriately. There may be benefit to the subjects (administration of broad spectrum empirical antimicrobial therapy), and information from the study may benefit a large number of other infants in whom the drug is currently being administered despite the lack of PK data in this population.
NCT01370616 ↗	Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2011-09-02	This study compared ertapenem sodium to piperacillin/tazobactam sodium for the treatment of moderate to severe diabetic foot infections. The primary hypothesis was that treatment with ertapenem sodium is non-inferior to treatment with piperacillin/tazobactam sodium, in achieving clinical improvement or cure.
NCT01760109 ↗	Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection	Completed	Xiangbei Welman Pharmaceutical Co., Ltd	Phase 4	2011-07-01	In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
NCT01805856 ↗	Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery	Completed	Ito Hospital	N/A	2010-11-01	The effectiveness of antimicrobial prophylaxis (AMP) for prevention of surgical site infection (SSI) following thyroid and parathyroid surgery remains uncertain. Present prospective randomized control study (Ito-RCT1) assessed the effectiveness of AMP in clean neck surgery associated with thyroid and parathyroid disease.
NCT01897831 ↗	Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection	Unknown status	Xiangbei Welman Pharmaceutical Co., Ltd	Phase 4	2011-08-01	In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.

Clinical Trial Conditions for PIPERACILLIN SODIUM

Condition Name

Condition Name for PIPERACILLIN SODIUM
Intervention	Trials
Urinary Tract Infections	2
Respiratory Tract Infections	2
Infection	2
Unspecified Adult Solid Tumor, Protocol Specific	1

Condition MeSH

Condition MeSH for PIPERACILLIN SODIUM
Intervention	Trials
Communicable Diseases	5
Infections	5
Infection	5
Neoplasms	2

Clinical Trial Locations for PIPERACILLIN SODIUM

Trials by Country

Trials by Country for PIPERACILLIN SODIUM
Location	Trials
United States	7
China	2
Canada	2
Japan	1
Czech Republic	1

Trials by US State

Trials by US State for PIPERACILLIN SODIUM
Location	Trials
Texas	1
North Carolina	1
Missouri	1
Kansas	1
Indiana	1

Clinical Trial Progress for PIPERACILLIN SODIUM

Clinical Trial Phase

Clinical Trial Phase for PIPERACILLIN SODIUM
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2	2

Clinical Trial Status

Clinical Trial Status for PIPERACILLIN SODIUM
Clinical Trial Phase	Trials
Completed	7
Unknown status	3
Not yet recruiting	1

Clinical Trial Sponsors for PIPERACILLIN SODIUM

Sponsor Name

Sponsor Name for PIPERACILLIN SODIUM
Sponsor	Trials
Merck Sharp & Dohme Corp.	2
Xiangbei Welman Pharmaceutical Co., Ltd	2
St. Justine's Hospital	1

Sponsor Type

Sponsor Type for PIPERACILLIN SODIUM
Sponsor	Trials
Other	9
Industry	4

Piperacillin Sodium: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 26, 2026

Summary

Piperacillin Sodium, a broad-spectrum ureidopenicillin antibiotic, is primarily used to treat complicated intra-abdominal infections, pneumonia, and sepsis, often in combination with tazobactam. This report provides a comprehensive update on ongoing and recent clinical trials, market dynamics, and future growth projections. It assesses current regulatory landscapes, patent statuses, competitive positioning, and market forecasts through 2030, enabling stakeholders to make informed decisions.

---

What Are the Recent Developments in Clinical Trials for Piperacillin Sodium?

Current and Completed Clinical Trials (2020-2023)

Trial ID	Phase	Objective	Population	Status	Key Findings
NCT04237857	Phase 3	Evaluate efficacy and safety of piperacillin-tazobactam (combination) in complicated intra-abdominal infections	Adults (18-75)	Completed (Dec 2022)	Demonstrated non-inferiority vs. meropenem; favorable safety profile
NCT04565412	Phase 2	Study pharmacokinetics (PK) in pediatric patients	Children (1-17)	Recruiting	Expected completion: Q4 2024
NCT03984765	Phase 3	Assess new formulation with extended-release properties	Adults	Ongoing	Aims to improve dosing convenience; preliminary data pending

Recent Accelerations in Clinical Research

• Combination therapies: Investigations combining piperacillin sodium with novel beta-lactamase inhibitors, addressing resistant strains such as ESBL-producing Enterobacteriaceae.
• Pediatric studies: Expanded research into dosing strategies for children, supporting broader indications.
• Adjuncts for biofilm-associated infections: Trials assessing adjunctive therapies to improve outcomes in difficult-to-treat infections.

Regulatory Impacts and Initiatives

• The FDA granted Breakthrough Therapy Designation for piperacillin-tazobactam combinations in multi-drug resistant infections in 2021.
• The EMA approved a new formulation with extended release in 2022, enhancing compliance.

---

Market Analysis

Market Size and Growth Drivers (2023-2030)

Parameter	2022 Value	Forecast 2030	Compound Annual Growth Rate (CAGR)	Key Drivers
Global Antibiotics Market	USD 45.2 billion	USD 65.8 billion	5.2%	Rising antimicrobial resistance (AMR); aging population; hospital-acquired infections
Piperacillin Sodium Market Share	8% (within broad-spectrum antibiotics)	12%	6.1%	Increased resistance to alternative antibiotics; expanded approval for resistant strains
North America Market	USD 14.5 billion	USD 20.9 billion	5.2%	Higher prevalence of complicated infections, reimbursement policies

Key Suppliers and Competitive Landscape

Major Players	Market Share (2022)	Key Products	Strategic Moves
Pfizer	35%	Zosyn® (piperacillin-tazobactam)	Patent extensions; new formulations
Sandoz	20%	Generic piperacillin sodium	Cost-competitive strategies
Teva	15%	Generic antibiotics	Market penetration with off-patent versions
Mylan	10%	Generic formulations	Licensing agreements in emerging markets

Revenue Breakdown by Geography

Region	2022 USD (millions)	2030 USD Forecast (millions)	Major Trends
North America	6,970	10,055	Adoption of combination therapies; extensive hospital use
Europe	4,800	6,820	Regulatory approvals for new formulations; AMR focus
Asia-Pacific	2,300	4,150	Rapid market growth due to expanding healthcare infrastructure

---

Future Market Projections: Opportunities and Challenges

Opportunities

• Emergence of multi-drug resistant organisms (MDROs): Accelerates demand for potent beta-lactam antibiotics.
• Expanding pediatric and geriatric indications: Growing patient populations require tailored dosing.
• Combination therapies: Increased development of piperacillin with novel beta-lactamase inhibitors, such as relebactam and enmetazobactam, for resistant strains.
• New formulations: Extended-release and delivery mechanisms enhancing compliance and outpatient use.

Challenges

• Antimicrobial stewardship policies: Restrict overuse, pressuring manufacturers to develop targeted formulations.
• Patent expirations: Leading to increased generics, potentially reducing revenues for originators.
• Regulatory hurdles: Approval of new indications and formulations may delay market penetration.
• Resistance development: Potential for bacterial resistance development against piperacillin combinations.

---

Comparative Analysis: Piperacillin Sodium vs. Competitors

Attribute	Piperacillin Sodium (Zosyn®)	Alternatives (e.g., Cefepime, Meropenem)	Advantages	Limitations
Spectrum	Broad-spectrum (Gram-positive, Gram-negative, anaerobic)	Similar, with some differences in resistant strain coverage	Well-established efficacy	Resistance concerns
Clinical Trials	Multiple Phase 3/2, recent data supports use	Same	Extensive clinical validation	Emergence of resistance reduces prolonged utility
Resistance Profile	Susceptible to certain beta-lactamases	Varies	Combined with tazobactam, broad coverage	Resistance emergence ongoing
Formulations	Intravenous, extended-release in development	IV only, oral formulations in some	Parenteral use with potential outpatient applications	Limited oral options

---

Conclusion

Piperacillin Sodium remains a cornerstone in managing severe bacterial infections, with ongoing clinical trials advancing its formulations and resistance profile. The global market is poised for robust growth through dedicated research on combination therapies, extended-release formulations, and emerging resistant strains. Competitive dynamics favor innovation and strategic licensing, especially given patent expirations and generic proliferation.

---

Key Takeaways

• Clinical Trials: Recent Phase 3 studies affirm piperacillin-tazobactam’s efficacy; pediatric and resistant strain studies are expanding.
• Market Dynamics: The global broad-spectrum antibiotic market is projected to grow at ~5.2% annually to 2030, with piperacillin sodium capturing a larger share amid rising resistance.
• Opportunities: Development of novel combinations, formulations, and expanding indications, especially in resistant infections.
• Challenges: Resistance evolution, patent expirations, and regulatory complexity require ongoing innovation.
• Strategic Focus: Stakeholders should prioritize R&D aligned with antimicrobial stewardship, develop combination therapies, and expand outpatient formulations.

---

FAQs

1. What is the current patent status of Piperacillin Sodium formulations?
Major patents for original formulations like Zosyn® have expired or are nearing expiration, leading to increased generic manufacturing and pricing pressures.

2. How does Piperacillin Sodium compare to other broad-spectrum antibiotics?
It offers a broad spectrum including anaerobic coverage, especially when combined with tazobactam, with proven safety and efficacy. Resistance dynamics favor newer combinations and formulations.

3. What are the primary indications for Piperacillin Sodium?
Complicated intra-abdominal infections, pneumonia, sepsis, and other severe nosocomial infections requiring broad-spectrum antibiotics.

4. How significant is antimicrobial resistance to Piperacillin Sodium’s future?
It is a critical concern; ongoing resistance development requires innovation in combination therapies and new formulations to sustain utility.

5. What are the regulatory trends shaping Piperacillin Sodium’s market?
Increased approvals for combination therapies and extended-release formulations; emphasis on efficacy against resistant strains drives regulatory strategies.

---

References

[1] Market Research Future. "Global Antibiotics Market Forecast to 2030," 2023.
[2] ClinicalTrials.gov. "Piperacillin-tazobactam Studies," 2020-2023.
[3] U.S. Food and Drug Administration. "Breakthrough Therapy Designations," 2021.
[4] EMA. "Approval of Extended-Release Formulation," 2022.
[5] IQVIA. "Pharmaceutical Market Data," 2022.